Daily Respiratory Research Analysis
Analyzed 216 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies stood out: a multicenter RCT showed that home-based, remotely supervised high-intensity interval training improves cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans. A prospective, multicountry diagnostic accuracy study evaluated a single multiplex Truenat assay for concurrent tuberculosis and COVID-19 testing, informing integrated respiratory diagnostics in LMICs. A large real-world self-controlled case series in severe asthma quantified biologic effectiveness and identified eligibility criteria that modify treatment effect.
Research Themes
- Remote rehabilitation and exercise physiology in pediatric chronic airway disease
- Integrated point-of-care molecular diagnostics for respiratory infections
- Real-world effectiveness and trial eligibility effects for biologics in severe asthma
Selected Articles
1. Home-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial.
In a multicenter, assessor-blinded RCT (n=51), home-based, real‑time remotely supervised HIIT for 16 weeks significantly improved peak oxygen consumption and functional capacity versus usual activity advice in children and adolescents with PIBO. The program was feasible in a rare pediatric airway disease population.
Impact: This is the first randomized trial demonstrating clinically meaningful exercise benefits via a scalable, home-based, remotely supervised program in PIBO, a rare chronic airway disease with limited therapeutic options.
Clinical Implications: Pulmonary rehabilitation for PIBO can be delivered remotely using HIIT to improve cardiorespiratory fitness and functional performance, supporting integration of tele-rehabilitation into pediatric chronic airway care pathways.
Key Findings
- Home-based, remotely supervised HIIT over 16 weeks improved peak oxygen consumption (VO2peak) versus control in PIBO.
- Functional capacity gains accompanied CRF improvements, indicating clinically meaningful benefit.
- The program was feasible and safe in a pediatric/adolescent population with a rare airway disease.
Methodological Strengths
- Assessor-blinded, multicenter randomized controlled design
- Pragmatic, real-time remote supervision enhances translational relevance
Limitations
- Modest sample size typical of rare disease RCTs limits precision
- Short- to mid-term outcomes; durability and clinical endpoints (exacerbations) not reported
Future Directions: Larger, longer trials should assess durability, impact on exacerbations, quality of life, and cost-effectiveness; mechanistic studies could define optimal HIIT dosing in pediatric airway remodeling.
INTRODUCTION: While high-intensity interval training (HIIT) has shown effectiveness in improving cardiorespiratory fitness (CRF) across various chronic respiratory diseases, its impacts on individuals with post-infectious bronchiolitis obliterans (PIBO) remain unexplored. AIM: To assess the effects of a home-based remotely-supervised HIIT programme on CRF, clinical and functional variables in patients with PIBO. METHODS: Participants of this assessor-blinded, multicentre, randomized controlled trial were individuals with PIBO aged 6 to 20 years. An exercise group (EXE) underwent two 40-min sessions of HIIT remotely supervised in real time per week. Sessions were continued for 16 weeks. The control group (CON) adhered to general physical activity recommendations. The primary outcome was peak oxygen consumption (VO RESULTS: Fifty-one PIBO patients were enrolled (EXE=25; CON=26) (mean age 13.3±4.2 years; females 49%; FEV
2. Diagnostic accuracy study of the multiplex Truenat MTB Ultima/COVID-19 assay for simultaneous detection of Tuberculosis and SARS-CoV2 (COVID-19).
In a prospective, multicountry diagnostic accuracy study (n=1,928), a single multiplex Truenat assay using a combined sputum plus nasopharyngeal specimen achieved 79.8% sensitivity and 98.9% specificity for TB, with COVID-19 sensitivity 64.4% and specificity 99.2%. Sensitivity for TB was lower than GeneXpert Ultra by ~9.5%, but the platform supports integrated respiratory testing workflows in LMICs.
Impact: This is a rare, prospective, multicountry evaluation of a multiplex point-of-care platform for TB and COVID-19 using a combined specimen, directly addressing disrupted TB programs and dual-disease differentiation.
Clinical Implications: Programs may adopt integrated testing workflows in respiratory clinics to maintain TB case finding during respiratory virus surges, using multiplex platforms where GeneXpert access is limited; however, confirmatory testing may still be needed when pretest probability is high.
Key Findings
- Overall TB sensitivity 79.8% (95% CI 76.0–83.2%) and specificity 98.9% (98.2–99.3%) using a combined sputum+NP specimen.
- TB sensitivity was ~9.5% lower than GeneXpert Ultra when directly compared on paired samples (82.8% vs 92.4%).
- COVID-19 detection sensitivity 64.4% (52.9–74.4%) and specificity 99.2% (98.7–99.5%), enabling dual-disease workflows.
Methodological Strengths
- Prospective, multicentre design across four countries with prespecified reference standards
- Trial registration and reporting of precision (Wilson’s score) improve transparency
Limitations
- Convenience sampling and combined specimen strategy may influence generalizability and operational feasibility
- Lower sensitivity than GeneXpert Ultra for TB and modest sensitivity for COVID-19 limit stand‑alone use
Future Directions: Optimization of sample workflows, head-to-head cost-effectiveness against existing platforms, and evaluation in decentralized settings during respiratory surges are warranted.
The COVID-19 pandemic led to significantly disrupted tuberculosis case detection and management. Additionally, overlapping symptoms, radiological findings and risk factors make differentiating tuberculosis and COVID-19 disease difficult. We conducted a prospective multicentre diagnostic accuracy study to determine sensitivity, specificity and operational characteristics of the Truenat MTB Ultima/COVID-19 assay, using a combined sputum plus nasopharyngeal swab specimen, in a single multiplex molecular assay. Participants were consenting adults with presumptive tuberculosis enrolled via convenience sampling from Uganda, Peru, South Africa, and India between August 2022 and December 2023. A microbiological reference standard of sputum GeneXpert MTB/RIF Ultra and culture was used for tuberculosis, whereas national RT-PCR was used for COVID-19. Wilson's score method was used to determine the sensitivity and specificity. Of 1,928 participants enrolled, median age was 38 years (IQR 28-50), 359/1928 (18.6%) previously had TB, and 287/1928 (14.9%) were HIV-positive. Overall prevalence of tuberculosis was 24.8% [95% CI 22.9-26.8%]. Prevalence of COVID-19 was 3.8% [3.1-4.8%] overall, and 4.7% [3.1-7.0%] in those with confirmed tuberculosis. Overall sensitivity of Truenat MTB Ultima/COVID-19 for tuberculosis was 79.8% [95% CI 76.0-83.2%]. When comparing paired samples, Truenat MTB Ultima/COVID-19 had a 9.5% [6.5-13.1%] decreased sensitivity against sputum TB culture, compared to GeneXpert Ultra; (82.8% [78.9-86.1%] vs 92.4% [89.4-94.5%]). Overall specificity of Truenat MTB Ultima/COVID-19 for tuberculosis was 98.9% [98.2-99.3%]. For COVID-19 detection, sensitivity of Truenat MTB Ultima/COVID-19 was 64.4% [52.9-74.4%], with specificity of 99.2% [98.7-99.5%]. Although optimal diagnostic performance was not demonstrated, the potential and need for rapid development of tests that integrate tuberculosis diagnosis with detection of other relevant respiratory infections is highlighted. The study was registered on ClinicalTrials.gov (NCT05405296).
3. A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE Study.
Using a self-controlled case series of 480 severe asthma patients within CHRONICLE, biologics reduced exacerbations (IRR 0.43, 95% CI 0.39–0.48), consistent with an RCT meta‑analysis (RR 0.53). Effect modification was significant for smoking history, prior exacerbations, FeNO, and blood eosinophils, while spirometry-based exclusions had limited influence on response.
Impact: This study bridges RCT evidence with real-world practice using a rigorous SCCS design, quantifying biologic effectiveness and identifying eligibility criteria that enrich or unnecessarily restrict trial populations.
Clinical Implications: Eligibility criteria emphasizing type 2 biomarkers (e.g., eosinophils, FeNO) and exacerbation history better enrich responders, whereas rigid spirometric exclusions may unnecessarily limit generalizability; findings support personalized biologic selection and smarter RCT designs.
Key Findings
- Biologics reduced severe exacerbation rates in SCCS (IRR 0.43; 95% CI 0.39–0.48), aligning with pooled RCT RR 0.53.
- Effect modification was significant for smoking history, prior exacerbations, FeNO, and blood eosinophil counts.
- Spirometry-based exclusions (e.g., fixed FEV1 cutoffs) had limited impact on treatment response, cautioning against overuse.
Methodological Strengths
- Self-controlled case series controls for time-invariant confounding within individuals
- Direct comparison with pooled RCT effects enhances external validity
Limitations
- Observational SCCS cannot fully exclude time-varying confounding
- Eligibility criteria operationalization may differ from original RCTs
Future Directions: Prospective, biomarker-enriched pragmatic trials and adaptive designs should refine patient selection while maximizing generalizability; health economic evaluations of enriched criteria are needed.
BACKGROUND: The trade-offs between regulatory preferences, trial success probability, and patient exclusion by eligibility criteria in randomised controlled trials (RCTs) of biologics for severe asthma remain poorly understood. We assessed biologic effectiveness and effect modification by nine RCT-derived criteria in a large real-world cohort of subspecialist-treated patients with severe asthma. METHODS: CHRONICLE was a multicentre, prospective, noninterventional cohort of US adults (aged ≥18 years) with severe asthma (NCT03373045). We performed a meta-analysis of six RCTs to estimate pooled rate ratios (RRs) for FDA-approved biologics and compared with incidence rate ratios (IRRs) from a self-controlled case-series (SCCS) using CHRONICLE data, analysing severe asthma exacerbation rates during biologic-exposed and unexposed periods. Subgroup analyses examined between-group comparisons (inclusion